WuXi PharmaTech Aids BASF Crop Protection Discover Research
Sep 06, 2006
September 6, Shanghai, China - WuXi PharmaTech, a leading provider of pharmaceutical R&D services in China, announced today that the extensive synthesis cooperation with BASF's central research units at Ludwigshafen and Limburgerhof has been very successful, and the number of chemists dedicated to BASF projects is now doubled.
WuXi PharmaTech helps the Agricultural Products division of BASF to synthesize chemical compounds that are needed in the wide-ranging quest for new active ingredients. These new compounds will eventually lead to innovative products and processes including new crop protection active ingredients.
Cooperation with partners throughout the world is an important aspect of the research strategy of BASF and BASF spends nearly Euro 100 million a year on more than 1,300 collaboration projects. According to Dr. Peter Eckes, Senior Vice President of Agricultural Products and Development, Global Crop-protection Research is the first unit of BASF to work together with a Chinese company.
"Cooperation with external partners makes a valuable contribution to the efficient organization of our research processes," said Dr. Alfred Hackenberger, President Specialty Chemicals Research "We enhance flexibility and can thus achieve even more with our research budget, for example by channelling more substances into screening in a shorter period of time. That is an important success factor because only a few of those substances turn out to be successful crop-protection active ingredients."
All external BASF partners are extensively scrutinized to make sure that no knowledge leaks out and that no potentially new active ingredients are jeopardized. Success factors in cooperation are unconditional reliability and open communication. Naturally, product quality and synthesis competence are evaluated because the BASF researchers have to be able to depend upon the partner in difficult situations to try everything they would also have attempted to achieve results.
"We are very pleased and honoured to be selected by BASF as its collaboration partner," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech, "This demonstrates our superior R&D service capability and capacity have been well recognized by our clients. We will continue improving our service quality and help our partners achieve their business goals sooner and more cost effectively."
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.